Merrimack Pharmaceuticals, Inc.

Third-quarter total operating expenses were $16.8 million, compared with $17 million from continuing operations in the same period last year, a decrease of $0.2 million year over year. The company ended the quarter with $84.8 million in cash, cash equivalents and marketable securities, versus $93.4 million at December 31, 2017. Management also said it received an $18 million milestone in August and a $5 million milestone in September, plus $5 million in October after quarter-end related to ONIVYDE. It estimated headcount restructuring charges of $1.5 million to $1.75 million. Forward-looking, Merrimack said the restructuring and potential additional cost actions could fund operations into at least the second half of 2022, compared with prior runway guidance into Q1 2020.

Richard Peters framed the quarter as a difficult reset, saying the company chose a corporate restructuring after SHERLOC showed MM-121 did not improve outcomes and after a broad portfolio review. He emphasized preserving cash, extending runway, and maintaining the ability to receive and ultimately pass through Ipsen-related milestones to shareholders, while keeping the focus on the most promising short-term value drivers. His tone was cautious but determined, repeatedly stressing that the changes were made to maximize long-term value.

Jean Franchi was absent, so Peters presented the financial update. He cited third-quarter operating expenses of $16.8 million, cash of $84.8 million at September 30, 2018, and $1.5 million to $1.75 million of estimated headcount restructuring charges. He also highlighted milestone receipts tied to ONIVYDE: $18 million in August, $5 million in September, and $5 million in October, and reiterated that Merrimack remains eligible for up to $450 million in regulatory milestones from Ipsen, which it expects to pass through to shareholders net of taxes and subject to surplus.

Analysts pressed for more detail on restructuring charges, the drop in MM-121-related R&D, and the pace of cost savings; management said the headcount-related charges should be $1.5 million to $1.75 million and that closing out SHERLOC and SHERBOC will take time. On MM-310, management explained that neuropathy appeared with cumulative/subsequent dosing, not as an isolated single-dose issue, and said the schedule change to every four weeks should improve tolerability without restarting escalation from scratch. Questions on the strategic review drew a response that external advisors have been engaged, the board directed the process, and Merrimack is keeping the scope open while trying to move swiftly.